TREATMENT OF PRIMARY ACUTE MYELOID LEUKEMIA WITH THE COMBINATION OF IDARUBICIN, CYTARABINE AND GEMTUZUMAB OZOGAMYCIN (MYLOTARG) ASSOCIATED OR NOT TO G-CSF PRIMING: PROSPECTIVE STUDY OF EFFICACY AND TOXICITY. Tratamiento de la leucemia mieloide aguda de novo con la combinacion de idarrubicina, citarabina y gemtuzumab ozogamicina (Mylotarg), asociada o no a "priming" con G-CSF. Estudio prospectivo de eficacia y toxicidad.

Trial Profile

TREATMENT OF PRIMARY ACUTE MYELOID LEUKEMIA WITH THE COMBINATION OF IDARUBICIN, CYTARABINE AND GEMTUZUMAB OZOGAMYCIN (MYLOTARG) ASSOCIATED OR NOT TO G-CSF PRIMING: PROSPECTIVE STUDY OF EFFICACY AND TOXICITY. Tratamiento de la leucemia mieloide aguda de novo con la combinacion de idarrubicina, citarabina y gemtuzumab ozogamicina (Mylotarg), asociada o no a "priming" con G-CSF. Estudio prospectivo de eficacia y toxicidad.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2016

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Granulocyte colony-stimulating factors; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2016 Planned End Date changed from 1 Feb 2013 to 1 Dec 2016.
    • 10 Aug 2016 Planned primary completion date changed from 1 Dec 2012 to 1 Dec 2016.
    • 05 Oct 2012 New source identified and integrated (ClinicalTrials.gov record NCT01698879).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top